share_log

Bruker Corp | 8-K: Bruker Reports Third Quarter 2024 Financial Results

Bruker Corp | 8-K: Bruker Reports Third Quarter 2024 Financial Results

布鲁克 | 8-K：布鲁克公布2024年第三季度财务业绩
美股SEC公告 ·  2024/11/05 06:01

Moomoo AI 已提取核心信息

Bruker reported Q3 2024 revenues of $864.4M, up 16.4% YoY, with organic revenue growth of 3.1% and CER revenue growth of 15.7%. BSI segment organic revenue increased 3.8% YoY. Q3 GAAP operating income was $68.1M, while non-GAAP operating income reached $129.1M with a 14.9% margin. GAAP diluted EPS was $0.27 and non-GAAP diluted EPS was $0.60.The company updated its FY2024 guidance, now expecting revenues of $3.34-3.37B, implying organic revenue growth of 3-4% and CER revenue growth of approximately 13% YoY. Non-GAAP EPS guidance was lowered to $2.36-2.41, reflecting delays in biopharma and China market recovery.Management noted gradual improvement in orders for differentiated post-genomic, multiomics, cleantech, semicon and diagnostics solutions, with BSI organic bookings growing in upper mid-single digits in Q3. The company remains confident in driving above-market organic revenue growth with significant margin expansion in 2025.
Bruker reported Q3 2024 revenues of $864.4M, up 16.4% YoY, with organic revenue growth of 3.1% and CER revenue growth of 15.7%. BSI segment organic revenue increased 3.8% YoY. Q3 GAAP operating income was $68.1M, while non-GAAP operating income reached $129.1M with a 14.9% margin. GAAP diluted EPS was $0.27 and non-GAAP diluted EPS was $0.60.The company updated its FY2024 guidance, now expecting revenues of $3.34-3.37B, implying organic revenue growth of 3-4% and CER revenue growth of approximately 13% YoY. Non-GAAP EPS guidance was lowered to $2.36-2.41, reflecting delays in biopharma and China market recovery.Management noted gradual improvement in orders for differentiated post-genomic, multiomics, cleantech, semicon and diagnostics solutions, with BSI organic bookings growing in upper mid-single digits in Q3. The company remains confident in driving above-market organic revenue growth with significant margin expansion in 2025.
布鲁克报告2024年第三季度营业收入为86440万美元，同比增长16.4%，有机营业收入增长3.1%，按固定汇率计算营业收入增长15.7%。BSI部门的有机营业收入同比增长3.8%。第三季度GAAP运营收入为6810万美元，而非GAAP运营收入达到12910万美元，利润率为14.9%。GAAP摊薄后每股收益为0.27美元，非GAAP摊薄后每股收益为0.60美元。公司更新了2024财年的指导，预计营业收入为334-337亿美元，意味着有机营业收入增长3-4%，按固定汇率计算营业收入同比增长约13%。非GAAP每股收益指导下调至2.36-2.41美元，反映了生物制药和中国市场复苏的延迟。管理层指出，针对差异化后基因组学、多组学、清洁技术、半导体和诊断解决方案的订单逐渐改善，BSI的有机订单在第三季度增长了中上个位数。公司对在2025年实现超出市场的有机营业收入增长并显著扩大利润率充满信心。
布鲁克报告2024年第三季度营业收入为86440万美元，同比增长16.4%，有机营业收入增长3.1%，按固定汇率计算营业收入增长15.7%。BSI部门的有机营业收入同比增长3.8%。第三季度GAAP运营收入为6810万美元，而非GAAP运营收入达到12910万美元，利润率为14.9%。GAAP摊薄后每股收益为0.27美元，非GAAP摊薄后每股收益为0.60美元。公司更新了2024财年的指导，预计营业收入为334-337亿美元，意味着有机营业收入增长3-4%，按固定汇率计算营业收入同比增长约13%。非GAAP每股收益指导下调至2.36-2.41美元，反映了生物制药和中国市场复苏的延迟。管理层指出，针对差异化后基因组学、多组学、清洁技术、半导体和诊断解决方案的订单逐渐改善，BSI的有机订单在第三季度增长了中上个位数。公司对在2025年实现超出市场的有机营业收入增长并显著扩大利润率充满信心。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    艾里德克斯
    IRIX
    -- 0.999
    Helius Medical Technologies
    HSDT
    -- 0.4200
    VolitionRX
    VNRX
    -- 0.550
    HeartSciences
    HSCS
    -- 2.9600
    Outset Medical
    OM
    -- 12.580
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日